Check-Cap, a colorectal cancer screening capsule endoscopy company, intends to raise $60 million for an initial public offering, according to a Bloomberg Business Week report.
The company's colon capsule is not yet for sale. Check-Cap expects to receive regulatory approval in the European Union in 2015 and approval in the United States in 2016.
Israel-based Check-Cap has financial backers including GE Capital and GE Healthcare and Pontifax Venture Capital Fund.
More articles on gastroenterology:
American Journal of Gastroenterology seeks editor-in-chief
3 GI/endoscopy devices receive FDA 510(k) clearance in August
Cost effectiveness & quality: 5 recent studies on colonoscopy
The company's colon capsule is not yet for sale. Check-Cap expects to receive regulatory approval in the European Union in 2015 and approval in the United States in 2016.
Israel-based Check-Cap has financial backers including GE Capital and GE Healthcare and Pontifax Venture Capital Fund.
More articles on gastroenterology:
American Journal of Gastroenterology seeks editor-in-chief
3 GI/endoscopy devices receive FDA 510(k) clearance in August
Cost effectiveness & quality: 5 recent studies on colonoscopy